- Home
- MBOT vs MSLE Comparison
MBOT vs MSLE Comparison
Compare MBOT & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBOT | MSLE |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.7M | 146.9M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | MBOT | MSLE |
|---|---|---|
| Price | $2.39 | $6.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 103.1K |
| Earning Date | 03-26-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,887.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4,200.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $6.67 |
| 52 Week High | $4.62 | $13.39 |
Technical Indicators
Market Signals| Indicator | MBOT | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 46.46 | 26.32 |
| Support Level | $2.34 | N/A |
| Resistance Level | $2.64 | $8.37 |
| Average True Range (ATR) | 0.15 | 0.88 |
| MACD | -0.04 | -0.21 |
| Stochastic Oscillator | 8.91 | 2.25 |
Price Performance
Historical ComparisonAbout MBOT Microbot Medical Inc.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.